Full-Time

Senior Manager

Commercial Data & Analytics

Posted on 8/12/2025

Element Science

Element Science

51-200 employees

Wearable defibrillator for sudden cardiac arrest

Compensation Overview

$170k - $180k/yr

+ Stock Options

No H1B Sponsorship

San Francisco, CA, USA

In Person

Category
Operations & Logistics (1)
Required Skills
Power BI
Python
R
Machine Learning
Tableau
Salesforce
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in Business, Analytics, Information Systems, or related field. Master’s degree preferred.
  • 7+ years of experience in Commercial Operations, Data Analytics, or Business Systems in MedTech, Biotech, or related industries.
  • Proven ability to design and deliver integrated commercial analytics and reporting in a high-growth, regulated environment.
  • Hands-on experience with Salesforce, Tableau, RCM tools, and integration software.
  • Proficiency in applying AI-driven analytics (e.g., predictive modeling, natural language processing, or machine learning-enabled dashboards) to uncover actionable insights and improve commercial performance.
  • Strong understanding of sales tools, CRM, and data architecture that supports commercialization.
  • Excellent communication skills with experience presenting to executive leadership.
  • Ability to operate strategically while remaining hands-on in technical build and execution.
  • Strong problem-solving, project management, and cross-functional collaboration skills.
Responsibilities
  • Design and manage the data architecture and reporting ecosystem across Commercial, Customer Success, Marketing, and Field Operations.
  • Build and maintain integrations across Salesforce, RCM, Niko Health, distribution platforms, patient communication software, and sales enablement tools.
  • Develop Tableau dashboards, reports, and KPIs that provide visibility into pipeline, productivity, patient engagement, and adoption trends.
  • Leverage AI/ML tools and automation to identify trends, forecast performance, and support proactive decision-making.
  • Partner with Commercial, Finance, and IT/IS teams to define technical requirements and implement scalable data solutions.
  • Ensure data accuracy, compliance, and integrity across all commercial systems and reporting environments.
  • Provide analytics and insights to support executive reviews, Board updates, and investor reporting.
  • Serve as the CRM owner (Salesforce), ensuring data integrity, process consistency, and system optimization.
  • Identify and implement sales process improvements and workflow automation to enhance efficiency and scalability.
  • Generate regular and ad-hoc reports to track sales performance, pipeline health, and key commercial metrics.
  • Support sales compensation administration, including data validation, reporting, and commission calculations.
  • Partner with Marketing on lead management—from routing and qualification to performance tracking.
  • Develop and maintain documentation for sales and operational processes to ensure consistency and transparency.
  • Work cross-functionally with Sales, Marketing, Finance, Quality, and Customer Success to align insights with business priorities.
  • Support sales enablement through data-driven tools, dashboards, and materials that increase field and inside sales effectiveness.
  • Drive adoption of analytics tools and create a culture of data-informed decision-making across the commercial organization.

Element Science creates medical devices to prevent sudden cardiac arrest. Its flagship product, Jewel, is a wearable external defibrillator intended to provide around-the-clock protection by monitoring the heart and delivering a life-saving shock when needed. Jewel is not yet commercially available in the U.S. This device works by continuously monitoring cardiac rhythm and, if a dangerous rhythm is detected, delivering a controlled electrical defibrillation; it is designed for use by at-risk individuals under medical guidance. The company differentiates itself by focusing on a wearable, user-friendly defibrillator and by prioritizing workforce diversity, equity, inclusion, and belonging (DEIB), as well as growth through team expansion. Element Science aims to bring Jewel to market, work with healthcare providers and insurers, increase accessibility for patients at risk of sudden cardiac arrest, and grow its market share while reducing deaths from cardiac events.

Company Size

51-200

Company Stage

Series C

Total Funding

$183.1M

Headquarters

San Francisco, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Appointed Lee Smith Jr. as Head of Commercial for global launch.
  • Named to Fast Company's 2026 Most Innovative Companies list.
  • Early U.S. launch in select states with expansion plans.

What critics are saying

  • ZOLL's LifeVest holds 90% market share blocking reimbursements.
  • Insufficient sales infrastructure delays U.S. ramp-up post-2025 PMA.
  • NHS England denies reimbursement citing ZOLL's cost-effectiveness.

What makes Element Science unique

  • Jewel Patch-WCD uses patch design unlike garment-based WCDs.
  • Received FDA PMA in April 2025 for U.S. commercialization.
  • Earned CE and UKCA Marks for European market entry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Stock Options

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Paid Vacation

Paid Holidays

FSA (Flexible Spending Accounts)

HSA (Health Savings Account)

Employee Assistance Program through PEO

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

-3%

2 year growth

1%
Business Wire
Mar 24th, 2026
Element Science named one of the world's most innovative companies by Fast Company

Element Science, a San Francisco-based health technology company, has been named to Fast Company's World's Most Innovative Companies of 2026 list. The company developed the Jewel Patch Wearable Cardioverter Defibrillator, which monitors and protects cardiovascular patients from sudden cardiac arrest. The Jewel Patch-WCD received FDA approval in April 2025 and European CE mark certification in January 2024. The device is water-resistant, discreet and requires no daily maintenance, distinguishing it as the only wearable cardioverter defibrillator that can be worn whilst showering. The product is currently in early commercial launch across select US states, targeting over 500,000 patients in the US and Europe at temporary risk of sudden cardiac arrest. Element Science's investors include Third Rock Ventures, Google Ventures and Deerfield Management.

Valdosta Daily Times
Jul 8th, 2024
Element Science Receives Prestigious International Red Dot Design Award for Innovative Jewel(R) Patch Wearable Cardioverter Defibrillator

Element Science, an innovative health technology company pioneering a digital wearable platform that monitors and protects high-risk cardiovascular patients, announces that its Jewel(R) Wearable Patch Cardioverter Defibrillator (Jewel) has received the prestigious Red Dot Design Award.

Business Wire
May 15th, 2024
Element Science Appoints Lee Smith, Jr. As The Company'S First Head Of Commercial

With nearly 20 years of successful leadership experience in sales strategy, commercial operations, and customer success, Mr. Smith will be instrumental in driving the launch and expansion of Element Science's Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) in globally markets. (Photo: Business Wire)With nearly 20 years of successful leadership experience in sales strategy, commercial operations, and customer success, Mr. Smith will be instrumental in driving the launch and expansion of Element Science's Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) in globally markets. (Photo: Business Wire)SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company developing a pioneering digital wearable platform for high-risk cardiovascular patients, announced the appointment of Lee Smith Jr. as the company's first Head of Commercial

Business Wire
Jan 25th, 2024
Element Science Receives Ce Mark Ukca Mark For The Jewel® Patch-Wearable Cardioverter Defibrillator

Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest. (Photo: Business Wire)Element Science Receives CE Mark & UKCA Mark for the Jewel® Patch-Wearable Cardioverter Defibrillator First of its kind life-saving technology receives CE Mark and UKCA Mark, paving the way for enhanced protection of patients with elevated risk of sudden cardiac arrest. (Photo: Business Wire)SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients, announced that it has received the European Union’s CE mark certification and Great Britain’s UK Conformity Assessed (UKCA) marking for its novel Patch Wearable Cardioverter Defibrillator (P-WCD) from its Notified Body, the BSI Group.The Jewel P-WCD was designed to address limitations with traditional garment-based WCDs. While these garment-based WCDs have demonstrated the ability to treat sudden cardiac arrest (SCA), a leading cause of death in the United States and in Europe, challenges related to patient comfort and compliance have resulted in avoidable deaths and limited their widespread adoption.The effectiveness of the Jewel defibrillator was confirmed in the Jewel EP Lab Study, conducted in Prague, Czech Republic, in which 16 patients experiencing ventricular arrhythmias were successfully converted to a normal heart rhythm after a single therapeutic shock. The Jewel IDE Study, a pivotal study of 305 patients presented at the American Heart Association’s 2023 Annual Scientific Sessions demonstrated significant patient compliance and protected time resulting in a high number of successful patient saves and no deaths or serious adverse events related to the device (www.ElementScience.com/ide-study/ ).Dr. Uday N

Business Wire
Oct 26th, 2022
Element Science Appoints Trish Howell As Chief Operating Officer | Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, announced that Trish Howell has been appointed as the Company’s new Chief Operating Officer, effective October 17, 2022. “ Ms. Howell is a transformational leader who has excelled in her positions prior to joining Element Science. As an innovative and seasoned executive, she expands the capabilities of our leadership team at an inflection point of our growth. Her experience in building successful commercial operations at medical device companies gives her a critically valuable perspective that will be an indispensable asset as we look forward to commercializing our technology and expanding our pipeline of products,” said Uday N. Kumar, MD, Founder, President and CEO

INACTIVE